Request Resource Shipment

Request Resource Shipment

Complete the form below to receive brochures and other educational materials about Aggrastat® for your clinic or hospital.

Please indicate the quantity of each you would like us to ship.

Aggrastat® Resources

Reimbursement Guide:
Ordering Guide:
Implementation Overview:
Creatinine Clearance Calculator Slider:

Aggrastat® Bolus Vial (250 mcg/mL)

GPI Per-Patient Acquisition Comparisons:
User Guide:
Dosing Guide:
Pocket Dosing Cards:

Aggrastat® 100 mL Vial/250 mL Bag (50 mcg/mL Units)

GPI Per-Patient Acquisition Comparisons:
User Guide:
Dosing Guide:
Pocket Dosing Cards:

Contact Information

First Name:
Last Name:
E-mail:
Phone:
Title:
Hospital / Clinic:
Address:
Address Line 2:
City:
State:
Zip Code:
 
Comments:

I am also interested in receiving additional communications from Medicure Pharma.

 

All Personal Information Will Be Kept Confidential And Will Not Be Shared With Any Parties Other Than Medicure And Its Designated Partners. Click Here To View Our Full Privacy Policy.

IMPORTANT SAFETY INFORMATION

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.

Unite Interactive